Introduction
============

Asthma and allergic rhinitis (AR) are both chronic inflammatory diseases of the airways and may share a common pathophysiology.[@b1-jaa-11-293],[@b2-jaa-11-293] They frequently coexist with as many as 80% of asthma patients reported to have AR and \~15%--40% of AR patients reported to have asthma.[@b3-jaa-11-293]--[@b6-jaa-11-293] Rhinitis is a significant risk factor for adult-onset asthma[@b3-jaa-11-293],[@b7-jaa-11-293],[@b8-jaa-11-293] and, compared with asthma alone, patients with coexistent asthma-AR are more likely to have uncontrolled asthma,[@b3-jaa-11-293],[@b9-jaa-11-293]--[@b11-jaa-11-293] experience a greater number of asthma attacks,[@b12-jaa-11-293]--[@b14-jaa-11-293] and report worse quality of life.[@b15-jaa-11-293],[@b16-jaa-11-293] Although there has been a high prevalence of coexistent asthma-AR reported in some low- and middle-income countries, consistent with that reported in higher income countries,[@b3-jaa-11-293],[@b17-jaa-11-293]--[@b19-jaa-11-293] there is a potential for underdiagnosis and suboptimal management of coexistent disease in low- and middle-income countries, possibly related to a lack of awareness and low public health prioritization in relation to these diseases.[@b17-jaa-11-293],[@b20-jaa-11-293],[@b21-jaa-11-293]

The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines recommend that patients with persistent AR should be routinely evaluated for asthma, and patients with asthma should be assessed for rhinitis.[@b3-jaa-11-293] The guidelines also recommend a combined strategy for treating the upper and lower airways, citing the co-administration of intranasal (INS) and inhaled corticosteroids (ICS) as the most effective medications for coexistent asthma-AR.[@b3-jaa-11-293] The ARIA guidelines are cited in the Global Initiative for Asthma (GINA) report where coexistent AR with asthma is identified as a contributor towards suboptimal symptom control.[@b22-jaa-11-293] However, GINA places less emphasis on the importance of a combined strategy to treat the coexistent asthma-AR,[@b22-jaa-11-293] vs the ARIA guidelines which recommend treatment with INS and ICS, suggesting a lack of consistency between the two sets of recommendations.

Previously, the Asthma Insights and Managements surveys reported an underuse of ICS to treat asthma together with an overuse of oral steroids in the Asia-Pacific region compared with the US, Canada, and Europe.[@b23-jaa-11-293] Knowledge gaps in the management of coexistent asthma-AR were also highlighted in a recent cross-sectional survey of physicians in China, in which a fifth of those surveyed reported the use of oral leukotriene antagonists as the most commonly used drug for treating AR while also controlling asthma.[@b24-jaa-11-293]

Considering the diversity of treatment practice, the Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis (ASPAIR) study aimed to assess physician attitudes and beliefs about coexistent asthma-AR, together with their management and treatment practices, across six countries. This paper describes the core results for the total physician population sampled.

Materials and methods
=====================

Study design and participants
-----------------------------

This was a cross-sectional survey of general physicians (primary care and hospital-based) and pediatricians who routinely treated adult and/or pediatric asthma patients (at least 10 month), in China, India, Malaysia, the Philippines, Thailand, and Vietnam (GSK Study 206753). Physician specialists (respiratory and non-respiratory) were excluded. In China, all levels of care, including primary care, are provided in hospital/clinic settings; therefore, all physicians were hospital-based general practice/internal medicine physicians, consistent with primary care physicians in other countries.

A probability-based sampling methodology was used to obtain a representative national sample of physicians across regions in each country, comprising \~200 physicians per country (50% general physicians and 50% pediatricians) giving a total sample size of 1,204. At selected sites, physicians were identified randomly using a number generator with the aim of obtaining four completed interviews out of 16 physicians identified. A maximum number of four completed interviews (two general physicians and two pediatricians) were allowed per facility.

The survey protocol and consent procedure were reviewed by an institutional review board, and this study was granted an exemption as the criteria for exemption were met under 45 CFR 46.101.(b)(2) of the US Code of Federal Regulations. The protocol included an Adverse Event protocol (no issues events were reported), data safety plan to ensure confidentiality and data safety, voluntary consent, disclosure of the survey sponsor, and informed right to withdraw at the end of the survey.

Questionnaire
-------------

A standardized questionnaire was developed with key external and local country experts and covered the following topics: attitudes and beliefs about coexistent asthma-AR, management and treatment practices for these patients, and knowledge and adherence to GINA and ARIA guidelines. The survey was administered via face-to-face interviews in the local language using Computer-Assisted Personal Interviewing tablets or laptops. Physicians were asked the questions by a professional interviewer and took the format of a multiple-choice list of answers from which to choose, an open-ended question with no specified list of answers, or response using a 5-point Likert scale (ranging from "strongly agree" to "strongly disagree"). The average interview length was 31 minutes (range 28 minutes \[India\] to 33 minutes \[Philippines\]), and the response rate by country ranged from 51% (India) to 72% (Malaysia).

Data analysis
-------------

Descriptive data summarizing physician responses are presented as unadjusted means, medians, frequencies, and/or proportions. Physician responses are presented as unadjusted statistics to be reflective of the full sampled populations. These physician sample data are not weighted because standardized and reliable estimates of the key demographic parameters of the universe of physicians in each country were not readily available and were not weighted overall due to the disproportionate size of countries.

Comparisons of demographic characteristics between countries were analyzed using a Z-test or Fisher's exact test for counts with n≤5. The Kruskal--Wallis non-parametric test was used to compare physicians' preferred treatment for coexistent asthma-AR, testing against an expected equal distribution of cases across countries. All tests were conducted using IBM SPSS Statistics software.

Results
=======

Physician demographics
----------------------

In the total sample of physicians across all six countries, over half were female physicians (53%), consistent across countries except India (25%) ([Table 1](#t1-jaa-11-293){ref-type="table"}). There was generally an equal distribution across the working population ages, but age distribution varied across countries. There was a higher proportion of younger physicians in Malaysia and Vietnam (\>70% in each country were younger than 45 years) and a quarter of physicians in India and the Philippines were older than 55 years. Sixty eight percent of physicians were hospital-based with the highest proportion of hospital physicians observed in China (100%; a factor of the healthcare system) and Thailand (86%). Other countries had a more even distribution between clinic-based and hospital-based physicians. In each country, only a small proportion of physicians worked in government clinics (≤14%) apart from Vietnam (38%). For the whole sample, the mean number of years worked in clinical practice was 15.5 years, which was broadly similar across countries. Most physicians had received some form of additional training in the management of asthma and AR, but the proportion was higher in relation to asthma (83%) vs AR (68%), similar in the six countries surveyed. Statistically significant differences in demographic characteristics between countries are summarized in [Table 1](#t1-jaa-11-293){ref-type="table"}.

Beliefs and practices about coexistent asthma-AR and its diagnosis
------------------------------------------------------------------

Overall, physicians reported 45% of their asthma patients as having coexistent AR (range 34%--50%) and 37% of their AR patients as having coexistent asthma (range 28%--46%). While 77% of physicians surveyed strongly or somewhat agreed that coexistent asthma-AR is a genuine condition with therapeutic consequences (range 67%--85%), more than a quarter of physicians sampled in India, the Philippines, and Vietnam strongly or somewhat agreed that patients with coexistent disease do not require different treatment to patients with one condition ([Figure 1A and B](#f1-jaa-11-293){ref-type="fig"}).

Approximately 70% of physicians confirmed that they questioned their asthma patients about AR symptoms and their AR patients about symptoms of asthma at every clinic visit. Physicians in all countries most commonly assessed the history of nasal symptoms to diagnose AR in asthma patients (88%, range 74%--100%) ([Table S1](#SD1-jaa-11-293){ref-type="supplementary-material"}). History of eye symptoms (50%) was commonly used in Thailand (78%) and India (75%) and least cited by physicians in the Philippines (8%) and Vietnam (17%), and family history of AR (47%) was used by \>50% of physicians in China, India, and Thailand but cited by just 16% of physicians in Vietnam. Similarly, in all countries, the most common criterion physicians used to diagnose asthma in AR patients was symptoms of asthma (91%, range 78%--100%). A family history of asthma was also commonly used by the physicians interviewed in China, India, and Thailand (\>70% of physicians) but was less common in Vietnam (28%), Malaysia (31%), and the Philippines (34%). Approximately a third of physicians measured lung function to diagnose asthma, most frequently physicians interviewed in China (57%) and Thailand (50%) but only 5% of physicians questioned in the Philippines and 17% in Malaysia ([Table S1](#SD1-jaa-11-293){ref-type="supplementary-material"}).

Assessment of asthma control
----------------------------

When assessing asthma control in patients with coexistent asthma-AR, physicians in all countries surveyed used the type and frequency of symptoms most commonly (84%; range 72%--92%) ([Table S2](#SD2-jaa-11-293){ref-type="supplementary-material"}). Other responses showed different trends across countries; for example, number of nighttime awakenings was used by over half of the physicians surveyed in India (63%), China (55%), and Thailand (52%), but by only 4% and 7% of physicians in Vietnam and the Philippines, respectively. Physicians in Thailand also considered the number of exacerbations and negative impacts on daily activities as important criteria for assessing control (reported by 66% and 65% of physicians, respectively). Of note, monitoring the frequency of short-acting beta-agonist (SABA) use to assess asthma control was consistently low in all participating countries (11%), with physicians interviewed in India reporting the most frequent use (24%). Similarly, the use of patient-reported outcome (PRO) tools was also low (8%, range 1%--20%). On the other hand, 16% of physicians used patient/family feedback to monitor asthma control, and this was most commonly reported by physicians questioned in China (43%) and Thailand (30%) ([Table S2](#SD2-jaa-11-293){ref-type="supplementary-material"}). When asked about assessing asthma control in patients with asthma only, overall responses showed some similarities but were not entirely consistent; for example, physicians more commonly used frequency of nighttime awakenings (49%), frequency of SABA use (30%), and use of PRO tools (18%) ([Table S3](#SD3-jaa-11-293){ref-type="supplementary-material"}).

Physician perceptions about the impacts of coexistent asthma-AR on patients
---------------------------------------------------------------------------

Most physicians strongly or somewhat agreed that coexistent disease results in patients having worse asthma symptoms (86%, range 83%--92%) and worse AR symptoms (77%, 65%--87%), compared with either condition alone. Similarly, more than 80% of physicians reported that patients with both the conditions are more negatively affected by worse sleep and disrupted daily activities, and this high impact was broadly consistent across countries ([Figure 2A and B](#f2-jaa-11-293){ref-type="fig"}). However, a greater proportion of physicians interviewed reported that patients with asthma alone vs coexistent disease are more likely to have frequent unplanned clinic or emergency room visits (44% vs 42%) or hospitalizations due to an uncontrolled disease (56% vs 40%) ([Figure 3A and B](#f3-jaa-11-293){ref-type="fig"}). This pattern was similar across countries except for China where physicians reported that patients with coexistent asthma-AR are most likely to require additional, unplanned healthcare visits or hospitalization due to an uncontrolled disease vs either condition alone ([Figure 3A and B](#f3-jaa-11-293){ref-type="fig"}).

Beliefs and practices about the management and treatment of coexistent asthma-AR
--------------------------------------------------------------------------------

While most physicians answered "yes" to the question "do the guidelines provide sufficient information for treating a patient with uncontrolled coexistent asthma-allergic rhinitis?" (≥80% of physicians in all countries other than Malaysia \[67%\]), just less than half of all surveyed physicians strongly or somewhat agreed that the disease was not well-defined (44%, range 28% \[China\] to 60% \[Vietnam\]). Similarly, although most physicians strongly or somewhat agreed that both the conditions should be managed and treated (91%; range 85%--98%), two fifths of physicians strongly or somewhat agreed that it was difficult to effectively treat them at the same time (40%, range 23% \[Thailand\] to 59% \[India\]). In practice, 75% of physicians said that they manage both the conditions in patients with coexistent disease (76%, range 61% \[India\] to 91% \[Thailand\]); however, approximately a third of physicians interviewed in India, Malaysia, and Vietnam preferentially managed one condition ([Figure 4](#f4-jaa-11-293){ref-type="fig"}). Physicians surveyed in Vietnam (87%), the Philippines (61%), and India (55%) generally strongly or somewhat agreed with the statement "Managing and treating the more severe of conditions of coexistent asthma-allergic rhinitis is sufficient." Referrals to specialists were relatively low across all countries. Even for patients with uncontrolled coexistent asthma-AR, 39% of physicians stated that they would modify the patients' treatment themselves rather than refer to a specialist (range 29% \[China\] to 46% \[Philippines\]). In addition, 46% of physicians considered their patient to be "well managed" if the patient reported an improvement in either condition (range 10%--73%), and this belief was most commonly expressed by physicians surveyed in India (65%) and the Philippines (73%).

With respect to treatment for asthma, many physicians revealed that their asthma patients are treated with a SABA alone (41%), least commonly reported by physicians interviewed in Thailand (23%) and most commonly reported by physicians interviewed in Vietnam (55%). Among physicians prescribing controller medications, the most commonly prescribed were ICS (72% of physicians prescribing additional medication; range 34% \[Philippines\] to 90% \[China and Thailand\]) followed by leukotriene receptor antagonists (LTRA) (59%; range 43% \[Malaysia\] to 80% \[China\]), and ICS/long-acting beta-agonists (46%, range 11% \[Philippines and Vietnam\] to 79% \[Thailand\]) (response options were not read from a list).

Regarding treatment for coexistent asthma-AR, most physicians agreed (answered "yes") that additional medications are needed, compared with treating one condition alone (89%, range 82%--94%), and 83% of physicians responded that this involved prescribing treatment for both asthma and AR, consistently shown across countries except for India (51%). Although most physicians strongly or somewhat agreed that ICS and INS could be given concurrently to patients with asthma and AR, respectively (82%, range 68% \[India\] to 88% \[Thailand\]), 46% strongly or somewhat agreed that treating both the diseases required too much medication and 37% strongly or somewhat agreed that ICS therapy was associated with too many side effects. These concerns were particularly common in physicians surveyed in India (≥80%) and Vietnam (≥60%), and these beliefs were reflected in the treatments that the physicians had prescribed. The most commonly prescribed treatment (chosen from a given list) was a combination of ICS and INS (47% of physicians), with physicians interviewed in China most likely to prescribe this treatment (71%) and physicians interviewed in India, the Philippines, and Vietnam least likely (≤40% of physicians) (*P*\<0.001 for statistical difference across countries; [Table 2](#t2-jaa-11-293){ref-type="table"}). Other prescribed medications included a combination of oral LTRA and ICS (22%, range 6% \[China\] to 36% \[(Vietnam\]) and ICS and oral antihista mines (15%, range 5% \[China\] to 23% \[Malaysia\]) ([Table 2](#t2-jaa-11-293){ref-type="table"}). Approximately, a quarter of physicians surveyed strongly or somewhat agreed that, in children, ICS should be delayed for asthma (24%, range 7% \[Thailand\] to 36% \[India\]) and INS should be delayed for AR (25%; range 7% \[Thailand\] to 38% \[Vietnam\]), with ≥30% of physicians interviewed in China, India, and Vietnam expressing this view.

When questioned about what influences their treatment choice for patients with coexistent asthma-AR (open-ended question), use of practice guidelines was the most frequently reported (62%), with patient affordability (50%) and physician experience (49%) also commonly reported ([Table 3](#t3-jaa-11-293){ref-type="table"}). This varied across countries; for example, few physicians interviewed in the Philippines used guidelines (17%), affordability being the biggest consideration (70%), and 63% of the physicians interviewed in China relied on their own personal experience. More than half of all physicians interviewed (58%) strongly or somewhat agreed that taking therapy for both the conditions was inconvenient for patients (range 42% \[Thailand\] to 80% \[Vietnam\]) and 46% of physicians strongly or somewhat agreed that their patients prefer to take oral medications over inhalers and nasal sprays (range 29% \[Thailand\] to 58% \[Philippines\]) ([Figure 5](#f5-jaa-11-293){ref-type="fig"}).

Discussion
==========

The ASPAIR survey provides an opportunity to understand the views of physicians in the Asia-Pacific region with respect to coexistent asthma-AR, their beliefs about the individual conditions, and their knowledge of international guidelines with respect to managing coexistent disease. Overall, most physicians interviewed across the six countries strongly or somewhat agreed that asthma and AR can coexist, with its associated impacts on patients, and the need to manage and treat both the conditions. In addition, most physicians surveyed acknowledged the acceptability of the guidelines; however, when applying the guidelines, physicians frequently did not follow through the recommendations in terms of assessing both asthma control and preferred treatments.

The estimated prevalence of asthma in patients with AR in this survey (range 28%--46%) is consistent with that reported in other studies,[@b3-jaa-11-293],[@b4-jaa-11-293] but the prevalence of AR in patients with asthma (range 34%--50%) was lower than that in studies reported elsewhere.[@b3-jaa-11-293],[@b5-jaa-11-293],[@b6-jaa-11-293] This non-concordance may be related to patients who do not perceive their symptoms of AR as a disease and therefore do not come forward to be assessed and treated.[@b3-jaa-11-293] This possible underdiagnosis of coexistent AR highlights a potential health risk for patients who are more likely to have uncontrolled asthma if they have untreated symptoms of rhinitis[@b3-jaa-11-293],[@b9-jaa-11-293]--[@b11-jaa-11-293] and underlines the importance of physicians evaluating patients for the coexistence of either disease when one is already present and initiating appropriate management.

A key finding of this survey was the lack of agreement between physicians' acknowledgment of the guidelines and their application in clinical practice. This was particularly apparent with respect to the assessment and treatment of asthma, with 41% of surveyed physicians stating that their asthma patients are treated with a SABA alone and 59% confirming the use of an oral LTRA as a controller medication in addition to SABAs. An overuse of quick reliever medications to treat asthma together with an underuse of inhaled controller medications has been reported previously for the Asia-Pacific region in two large global patient surveys,[@b23-jaa-11-293],[@b25-jaa-11-293] conducted in 2009--2011 and 2009, respectively. GINA recommends using a SABA alone for patients with mild intermittent asthma only, the frequency of which is estimated to occur in \<40% of the total asthma population,[@b26-jaa-11-293] and suggests prescribing low-dose ICS for most asthma patients, even those with infrequent symptoms, to reduce the risk of serious exacerbations.[@b22-jaa-11-293] As few physicians across countries reported monitoring the frequency of SABA use to monitor asthma control (a GINA-recommended indicator of poor control), these data could signal an underuse of ICS in some patients, a risk factor for poor asthma outcomes.[@b22-jaa-11-293] The use of PRO tools to assess asthma control was also relatively low while approximately a fifth of physicians reported using feedback from the patient/family to assess asthma control. The recent Global Asthma Physician Survey (conducted in 2015 in Australia, Canada, China, France, Germany, and Japan) also reported a discrepancy between the measures used by physicians to assess asthma control and those recommended by GINA with less than a quarter of all physicians surveyed using the frequency of SABAs to assess asthma control and a smaller percentage utilizing PROs.[@b27-jaa-11-293]

The majority of physicians interviewed across all countries agreed that additional medications are required to treat coexistent asthma-AR, compared with treating one condition alone (in alignment with ARIA); however, only 47% stated their preferred treatment as a combination of ICS and INS (ARIA recommendation), with particularly low use cited by physicians interviewed in Vietnam (26%) and the Philippines (38%). The overall and country-specific rates need to be interpreted relative to the health systems and access to medications within the surveyed countries, though these may reflect physicians' concerns regarding overall steroid burden. This is a particular possibility as approximately a quarter of physicians strongly or somewhat agreed that corticosteroid therapy to treat asthma or AR should be delayed in children. This delay is clinically important as early intervention with ICS reduces the risk of exacerbations and is associated with long-term benefits on lung growth and airway obstruction.[@b22-jaa-11-293],[@b28-jaa-11-293]

Reassuringly, most physicians interviewed clearly recognized the impacts and increased burden of having coexistent disease vs one condition only, suggesting an understanding of the disease and its impacts on patients' everyday lives and quality of life, consistent with the evidence in the literature.[@b9-jaa-11-293]--[@b16-jaa-11-293] This was tempered by the level of non-concordance shown with ARIA guidelines in terms of managing the coexistent disease, as well as the interesting perception that patients with asthma alone were more likely to have unplanned emergency visits or hospitalization compared with those with coexistent disease, which was common across all countries with the exception of China. This is despite evidence demonstrating that patients with coexistent asthma-AR are more likely to experience a greater number of asthma attacks requiring healthcare resources, compared with asthma alone.[@b12-jaa-11-293]--[@b14-jaa-11-293] Another interesting finding was that 46% of physicians overall considered their patients to be well managed if either their asthma or AR improved, and this was particularly noted in physicians interviewed in India (65%) and the Philippines (73%), perhaps indicating a low level of understanding the true impact of one disease on the other or a poor expectation of what can be achieved through effective treatment of both the conditions. Overall, these data signal a call to action across the region to work on the promising building blocks that are already in place and to drive change by improving awareness of coexistent disease, encouraging physicians to actively look for and diagnose the disease together with the implementation of appropriate management and follow-up.

The inclusion of a generally representative sample of physicians, reflective of clinical practice across six countries, is a strength of this survey, as well as the high response rates showing a good level of engagement from the physicians approached. However, it must also be acknowledged that there may have been an over-sampling of urban vs rural physicians due to the sampling method used, and as countries in the Asia-Pacific region were represented, the reported findings may not be globally applicable in their entirety. In addition, this was a cross-sectional survey, and therefore, no conclusions about longitudinal behaviors can be derived from these results. A further important limitation may have been "social desirability bias," that is, physicians are aware of the guidelines and know that they should be following them, and so responses may reflect that. This may be particularly pertinent in the ASPAIR survey as interviews were in-person. To mitigate this, questions were spaced out during the interview to eliminate priming.

In conclusion, this large-scale survey of physicians in the Asia-Pacific region demonstrates widespread acceptance of the existence and associated burden of coexistent asthma-AR, together with an acknowledgement of the usefulness of the guidelines. However, there was a discordance between their beliefs and perceptions and their management and treatment practices with respect to applying the guideline recommendations to coexistent asthma-AR. These data highlight the need for increased healthcare practitioner awareness to improve appropriate diagnosis and management of coexistent asthma-AR, with the aim of improving outcomes and quality of life for patients.

Supplementary materials
=======================

###### 

Criteria to assess AR symptoms among asthma patients and asthma symptoms among AR patients

                                                                                                       Total   China   India   Malaysia   Philippines   Thailand   Vietnam
  ---------------------------------------------------------------------------------------------------- ------- ------- ------- ---------- ------------- ---------- ---------
  **Criteria to assess AR symptoms among asthma patients[a](#tfn9-jaa-11-293){ref-type="table-fn"}**                                                               
  History of nasal symptoms                                                                            88      100     95      74         78            97         79
  History of eye symptoms                                                                              50      61      75      45         8             78         17
  Family history of AR/atopy                                                                           47      59      66      33         28            71         16
  Symptoms due to seasonal allergens                                                                   46      79      61      23         6             58         33
  Symptoms due to recurring allergens                                                                  33      41      50      24         0             59         10
  Exposure to environmental hazards/pollutants                                                         30      38      37      24         24            28         26
  Skin prick or IgE testing                                                                            14      17      25      6          1             26         3
  Withdraw AR treatment/start trial AR treatment                                                       7       9       6       3          0             24         0
  Other responses combined                                                                             7       0       0       12         0             4          24
  **Criteria to diagnose asthma symptoms in AR patients[a](#tfn9-jaa-11-293){ref-type="table-fn"}**                                                                
  Clinical history of wheezing/SOB/chest tightness/cough                                               91      100     94      87         78            100        82
  Family history of asthma/atopy                                                                       56      79      85      31         34            72         28
  Exposure to common asthma triggers                                                                   43      74      57      32         14            63         9
  Lung function tests confirmation                                                                     34      57      40      17         5             50         26
  Reversibility/methacholine challenge                                                                 25      35      32      12         2             50         12
  Withdraw respiratory treatment/start trial respiratory treatment                                     4       1       6       1          1             16         0
  Guidelines (eg, GINA, ARIA)                                                                          2       0       0       12         0             0          0
  Exacerbations                                                                                        1       0       0       0          0             1          4
  Clinical examination                                                                                 2       0       0       0          0             1          13
  Other responses combined                                                                             5       0       0       2          0             3          22

**Notes:**

Responses to these questions were not elicited from a predetermined list. Values shown as %

**Abbreviations:** AR, allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on Asthma; IgE, immunoglobulin E; GINA, Global Initiative for Asthma; SOB, shortness of breath.

###### 

Most common criteria used to assess asthma control in asthma patients with AR (open-ended question)

                                                           Total (N=1,204)   China (N=200)   India (N=200)   Malaysia (N=202)   Philippines (N=200)   Thailand (N=200)   Vietnam (N=202)
  -------------------------------------------------------- ----------------- --------------- --------------- ------------------ --------------------- ------------------ -----------------
  Type and frequency of symptoms                           84                92              85              77                 72                    92                 76
  Frequency of nighttime awakenings                        36                55              63              16                 7                     52                 4
  Interference with normal activities apart from work      30                29              49              14                 0                     65                 6
  Interference with work or household work                 21                28              38              7                  0                     41                 1
  Interference with exercise                               20                43              28              8                  5                     26                 1
  Lung function with spirometry (FEV~1~) or peak flow      18                32              45              12                 4                     3                  4
  Number of exacerbations                                  29                30              40              5                  5                     66                 13
  Validated patient-reported outcomes via questionnaires   8                 20              16              5                  5                     2                  1
  Use of reliever bronchodilators for symptom control      11                11              24              12                 1                     9                  5
  Medication use and frequency, excluding SABAs            20                25              33              15                 0                     21                 12
  Medical history, including number of office visits       30                44              31              11                 8                     50                 22
  Patient or family feedback                               16                43              0               9                  0                     30                 2
  Examination or clinical evaluation                       31                38              45              12                 4                     55                 15
  Other responses combined                                 7                 1               0               0                  0                     1                  40

**Note:** Values shown as %.

**Abbreviations:** AR, allergic rhinitis; FEV1, forced expiratory volume in 1 sec; SABA, short-acting beta-agonist.

###### 

Most common criteria used to assess asthma control in asthma patients (open-ended question)

                                                           Total   China   India   Malaysia   Philippines   Thailand   Vietnam
  -------------------------------------------------------- ------- ------- ------- ---------- ------------- ---------- ---------
  Type and frequency of symptoms                           84      91      92      73         63            87         84
  Frequency of nighttime awakenings                        49      74      62      27         8             77         23
  Interference with normal activities apart from work      34      38      49      13         0             72         10
  Interference with work or household work                 27      37      36      10         1             55         4
  Interference with exercise                               33      57      32      22         8             58         5
  Lung function with spirometry (FEV~1~) or peak flow      32      58      47      11         11            42         11
  Number of exacerbations                                  38      45      40      8          10            89         17
  Validated patient-reported outcomes via questionnaires   18      28      25      19         3             24         2
  Use of reliever bronchodilators for symptom control      30      22      30      24         5             73         9
  Medication use and frequency, excluding SABAs            32      34      37      17         3             59         23
  Medical history, including number of office visits       35      45      34      18         1             54         36
  Patient or family feedback                               21      41      41      8          0             22         3
  Exam or clinical evaluation                              30      44      36      5          3             52         22
  Other responses combined                                 5       0       3       0          0             3          23

**Note:** Values shown as %.

**Abbreviations:** AR, allergic rhinitis; FEV1, forced expiratory volume in 1 sec; SABA, short-acting beta-agonist.
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![(**A**) Physician beliefs about the existence of coexistent asthma-AR. (**B**) Physician beliefs about the importance of treating coexistent asthma-AR.\
**Notes:** Total (n=1,204), China (n=200), India (n=200), Malaysia (n=202), Philippines (n=200), Thailand (n=200), Vietnam (n=202). Percentages for specific responses \<1%, not shown.\
**Abbreviation:** AR, allergic rhinitis.](jaa-11-293Fig1){#f1-jaa-11-293}

![Impact of coexistent asthma-AR on (**A**) sleep and (**B**) daily activities.\
**Note:** Total (n=1,204), China (n=200), India (n=200), Malaysia (n=202), Philippines (n=200), Thailand (n=200), Vietnam (n=202).\
**Abbreviation:** AR, allergic rhinitis.](jaa-11-293Fig2){#f2-jaa-11-293}

![Relative impact of asthma, AR, and coexistent asthma-AR on healthcare resource use: (**A**) frequent unplanned clinic or emergency room visits and (**B**) hospitalizations for an uncontrolled disease.\
**Note:** Total (n=1,204), China (n=200), India (n=200), Malaysia (n=202), Philippines (n=200), Thailand (n=200), Vietnam (n=202). Percentages for specific responses \<1%, not shown.\
**Abbreviations:** AR, allergic rhinitis; ER, emergency room.](jaa-11-293Fig3){#f3-jaa-11-293}

![Management of coexistent asthma-AR.\
**Notes:** Total (n=1,204), China (n=200), India (n=200), Malaysia (n=202), Philippines (n=200), Thailand (n=200), Vietnam (n=202). Percentages for specific responses \<1%, not shown.\
**Abbreviations:** AR, allergic rhinitis; ENT, ear-nose-throat specialist.](jaa-11-293Fig4){#f4-jaa-11-293}

![Physician beliefs about patients' treatment preferences.\
**Note:** Total (n=1,204), China (n=200), India (n=200), Malaysia (n=202), Philippines (n=200), Thailand (n=200), Vietnam (n=202).](jaa-11-293Fig5){#f5-jaa-11-293}

###### 

Demographic characteristics of physicians by country

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                               Total N=1,204   China N=200 (A)                                                                               India N=200 (B)                                         Malaysia N=202 (C)                                    Philippines N=200 (D)                                                                         Thailand N=200 (E)                                     Vietnam N=202 (F)
  -------------------------------------------- --------------- --------------------------------------------------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------
  **Age (years)**\                             \               \                                                                                             \                                                       \                                                     \                                                                                             \                                                      \
  \<35\                                        27\             11\                                                                                           10\                                                     47\                                                   15\                                                                                           31\                                                    50\
  (n=327)\                                     31\             43\                                                                                           34\                                                     ABD[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\   33\                                                                                           ABD[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\    ABDE[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\
  35--44\                                      26\             CF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\                                            F[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\           E[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}\       F[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\                                                 29\                                                    22\
  (n=372)\                                     13\             E[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}D[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\   33\                                                     25\                                                   27\                                                                                           26\                                                    17\
  45--54\                                      3\              35\                                                                                           CF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\      16\                                                   C[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}F[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\   CF[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}\       9\
  (n=309)\                                     NT              CF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\                                            18\                                                     5\                                                    19\                                                                                           16\                                                    1\
  55--64\                                                      E[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\                                                 C[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\       3\                                                    C[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\                                             C[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}\        NT
  (n=153)\                                                     10\                                                                                           AF[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\          NT                                                    F[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}A[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\   F[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\          
  \>65\                                                        1\                                                                                            7\                                                                                                            6\                                                                                            --\                                                    
  (n=35)                                                       NT                                                                                            NT                                                                                                            NT                                                                                            NT                                                     

  **Gender**\                                  \               \                                                                                             \                                                       \                                                     \                                                                                             \                                                      \
  Male\                                        47\             34\                                                                                           76\                                                     48\                                                   32\                                                                                           43\                                                    50\
  (n=566)\                                     53              66\                                                                                           ACDEF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\   AD[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}\      69\                                                                                           D[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\          D[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\
  Female\                                                      B[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\                                             25                                                      52\                                                   BF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\                                            57\                                                    A[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\
  (n=638)                                                      CF[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}                                                                                                       B[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}      C[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}E[\*](#tfn2-jaa-11-293){ref-type="table-fn"}    B[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}       50\
                                                                                                                                                                                                                                                                                                                                                                                                                                B[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}

  **Type of practice**\                        \               \                                                                                             \                                                       \                                                     \                                                                                             \                                                      \
  Government clinic/\                          13\             0\                                                                                            6\                                                      9\                                                    14\                                                                                           11\                                                    38\
  office\                                      50\             98\                                                                                           A[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\       A[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\     A[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\                                             A[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\      ABCDE[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\
  (n=155)\                                     19\             BCDEF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\                                         29\                                                     35\                                                   B[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}\                                               70\                                                    49\
  Government hospital\                         18              0\                                                                                            D[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\           D[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\     19\                                                                                           BCDF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\   BD[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\
  (n=598)\                                                     3                                                                                             32\                                                     43\                                                   35\                                                                                           5\                                                     C[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}\
  Private clinic/office\                                                                                                                                     AEF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\     AEF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\   AEF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\                                           A[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}\        3\
  (n=234)\                                                                                                                                                   34\                                                     B^a^\                                                 33\                                                                                           16\                                                    A[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\
  Private hospital\                                                                                                                                          ACEF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}     13\                                                   ACEF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}                                           A[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}       11\
  (n=217)                                                                                                                                                                                                            A[\*](#tfn2-jaa-11-293){ref-type="table-fn"}                                                                                                                                                               A[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}

  **Years in clinical practice**\              \               \                                                                                             \                                                       \                                                     \                                                                                             \                                                      \
  Mean\                                        15.5\           19.4\                                                                                         19.7\                                                   12.0\                                                 16.1\                                                                                         14.0\                                                  11.9\
  Median                                       14              CEF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\                                           CEF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\     9 (SD 9.4)                                            CF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\                                            CF[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\         9 (10.2)
                                                               D[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}\                                               D[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}\                                                               E[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\                                                 13 (SD 9.1)                                            
                                                               20 (SD 7.8)                                                                                   18 (SD 10.4)                                                                                                  15 (SD 10.7)                                                                                                                                         

  **Continuing medical education**\            \               \                                                                                             \                                                       \                                                     \                                                                                             \                                                      \
  Asthma management and treatment (n=1,000)\   83\             89\                                                                                           77\                                                     85\                                                   89\                                                                                           76\                                                    84\
  AR management and\                           68              BE[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}\                                              70\                                                     E[\*](#tfn2-jaa-11-293){ref-type="table-fn"}\         BE[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}\                                              66\                                                    63\
  treatment (n=818)                                            72\                                                                                           C[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}        53                                                    85\                                                                                           C[\*](#tfn2-jaa-11-293){ref-type="table-fn"}           C[\*](#tfn2-jaa-11-293){ref-type="table-fn"}
                                                               C[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}                                                                                                                                                            CEF[\*\*\*](#tfn4-jaa-11-293){ref-type="table-fn"}\                                                                                                  
                                                                                                                                                                                                                                                                           AB[\*\*](#tfn3-jaa-11-293){ref-type="table-fn"}                                                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Values shown as % unless stated otherwise.

*P*\<0.05,

*P*\<0.01,

*P*\<0.001 (95% confidence level).

**Abbreviation:** NT, not tested due to small sample size; SD, standard deviation.

###### 

Preferred treatment for coexistent asthma-AR

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                       Total N=1,204   China N=200   India N=200   Malaysia N=202   Philippines N=200   Thailand N=200   Vietnam N=202   *P*-value[a](#tfn6-jaa-11-293){ref-type="table-fn"}
  ------------------------------------------------------------------------------------ --------------- ------------- ------------- ---------------- ------------------- ---------------- --------------- -----------------------------------------------------
  Combination of inhaled corticosteroids and intranasal corticosteroids (*P*\<0.001)   47              71            40            52               38                  59               26              \
                                                                                                                                                                                                         \<0.001

  Combination of oral LTRA and inhaled corticosteroids (*P*\<0.001)                    22              6             20            16               34                  19               36              \
                                                                                                                                                                                                         \<0.001

  Only inhaled corticosteroids (*P*\<0.001)                                            4               1             10            1                3                   1                9               \
                                                                                                                                                                                                         \<0.001

  Only intranasal corticosteroids (*P*\<0.01)                                          2               3             5             0                1                   1                2               \
                                                                                                                                                                                                         \<0.01

  Oral corticosteroids and oral antihistamines (*P*\<0.01)                             6               8             10            3                7                   2                4               \
                                                                                                                                                                                                         \<0.01

  Inhaled corticosteroids and oral antihistamines (*P*\<0.001)                         15              5             11            23               17                  16               17              \
                                                                                                                                                                                                         \<0.001

  Only oral/inhaled antihistamines (*P*\<0.001)                                        1               5             3             0                0                   0                0               \
                                                                                                                                                                                                         \<0.001

  Only LTRA (NS, *P*\>0.05)                                                            1               1             3             2                1                   0                1               \
                                                                                                                                                                                                         NS

  Other responses combined (NS, *P*\>0.05)                                             2               2             1             2                1                   4                0               \
                                                                                                                                                                                                         NS
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Kruskal-Wallis Test. Values shown as %. Q. From the following pharmacological treatments, what is your preferred treatment for a patient with coexistent asthma-allergic rhinitis? 1) Combination of inhaled corticosteroids and intranasal corticosteroids. 2) Combination of oral anti-leukotrienes and inhaled corticosteroids. 3) Only inhaled corticosteroids. 4) Only intranasal corticosteroids. 5) Oral corticosteroids and oral antihistamines. 6) Inhaled corticosteroids and oral antihistamines. 7) Only oral/inhaled antihistamines. 8) Only LTRA. Physicians may also have answered 'Other' and been asked to specify, 'Do not know' or refused to answer'.

**Abbreviations:** AR, allergic rhinitis; NS, not significant (*P*\>0.05); LTRA, leukotriene receptor antagonist.

###### 

Factors influencing treatment choice

                                                             Total N=1,204   China N=200   India N=200   Malaysia N=202   Philippines N=200   Thailand N=200   Vietnam N=202
  ---------------------------------------------------------- --------------- ------------- ------------- ---------------- ------------------- ---------------- ---------------
  Practice guidelines                                        62              50            82            69               17                  86               53
  Physicians' personal experience                            49              63            85            49               8                   56               22
  Availability (in stock)                                    30              29            18            49               15                  45               19
  Treatment on the drug list or clinic/insurance formulary   19              31            13            27               0                   20               20
  Patient preference                                         25              34            16            34               10                  36               13
  Patient affordability                                      50              55            33            42               70                  51               54
  Other responses combined                                   0               0             0             0                0                   0                2

**Notes:** Q. What factors, excluding individual patient characteristics, influence your choice of treatment? (response options not read or shown to respondents). Values shown as %.
